We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

MICROBIOLOGICS INC.

Microbiologics is a biological products and services provider that partners with healthcare and life science laborato... read more Featured Products: More products

Download Mobile App





Microbiologics Introduces First SARS-CoV-2 RNA IVD CE Marked Control

By LabMedica International staff writers
Posted on 25 Mar 2020
Microbiologics, Inc. More...
(Saint Cloud, MN, USA) has launched a SARS-CoV-2 IVD control within its popular Helix Elite line of molecular controls to help accelerate COVID-19 assay development and increase access to testing. The new IVD product provides quality control measures for the development, verification, and validation of diagnostic tests, with the unmatched precision and convenience of the Helix Elite line.

Microbiologics partners with healthcare and life science laboratories, manufacturers and suppliers across the globe to co-create and provide biological control materials, assay services and consulting for microbiology, molecular diagnostics and virology.

Microbiologics’ SARS-CoV-2 Helix Elite control features a large RNA molecule that matches the sequence of the virus N gene (which codes for the nucleocapsid phosphoprotein found in the shell of the virus) and works with CDC-specified test components to generate positive PCR signals. The synthetic RNA control material is non-infectious and classified as BSL-1, remaining stable at room temperature to allow convenient shipping and storage. The Helix Elite SARS-CoV-2 IVD control is manufactured under ISO 13485 standards, and is designed for extended use and flexibility to match the hectic pace of high-volume testing. Microbiologics aims to continue developing resources for the global response to COVID-19, including IVD RNA controls with other gene sequences from the SARS-CoV-2 virus.

“With all the unknowns of this new coronavirus strain, third party IVD controls with the right genomic targets are more critical than ever,” said Marylou Gibson, Microbiologics’ Chief Virologist. “This new SARS-CoV-2 control comes with the proven quality of the Helix Elite product line to assure your test results.”

Related Links:
Microbiologics, Inc.


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Two major international studies identified noninvasive tests that can accurately diagnose and assess MASLD and MASH, reducing reliance on liver biopsy. (Image Credit: Adobe Stock)

Noninvasive Tests Offer Alternatives to Biopsy for Assessing Advanced Liver Scarring

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to one in three adults worldwide and as many as seven in 10 people with obesity or type 2 diabetes. Its more severe form, metabolic... Read more

Molecular Diagnostics

view channel
Image:Graphical Abstract (Victori P, Hua K, Twigger AJ, et al. Tumor digital twins uncover therapeutic strategies in triple-negative breast cancer. Cell Reports Medicine, 2026. doi:10.1016/j.xcrm.2026.103119.)

Digital Twins Predict Treatment Response in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive, fast-growing subtype that accounts for about 15% of all breast cancer cases. Its tumor cells lack estrogen receptors, progesterone receptors, and... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: Graphical Abstract (Andrew Medina-Marino, Chibuzor M Babalola, Mandisa M Mdingi, et al. Clinical Infectious Diseases, 2026. doi:10.1093/cid/ciag577.)

Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births

Preterm birth remains a major obstetric concern and is associated with serious complications in early childhood. Common sexually transmitted infections during pregnancy often cause no symptoms, making... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.